Advanced glycation end-products and the progress of diabetic vascular complications
- PMID: 15046548
Advanced glycation end-products and the progress of diabetic vascular complications
Abstract
Epidemiological studies have confirmed that hyperglycemia is the most important factor in the onset and progress of vascular complications, both in Type 1 and 2 diabetes mellitus. The formation of advanced glycation end-products (AGEs) correlates with glycemic control. The AGE hypothesis proposes that accelerated chemical modification of proteins by glucose during hyperglycemia contributes to the pathogenesis of diabetic complications including nephropathy, retinopathy, neuropathy and atherosclerosis. Recent studies have shown that increased formation of serum AGEs exists in diabetic children and adolescents with or without vascular complications. Furthermore, the presence of diabetic complications in children correlates with elevated serum AGEs. The level of serum AGEs could be considered as a marker of later developments of vascular complications in children with Type 1 and 2 diabetes mellitus. The careful metabolic monitoring of young diabetics together with monitoring of serum AGEs can provide useful information about impending AGE-related diabetic complications. It is becoming clear that anti-AGE strategies may play an important role in the treatment of young and older diabetic patients. Several potential drug candidates such as AGE inhibitors have been reported recently.
Similar articles
-
[Advanced glycosylation end products and chronic complications of diabetes mellitus].Gac Med Mex. 2003 Jan-Feb;139(1):49-55. Gac Med Mex. 2003. PMID: 12666409 Review. Spanish.
-
Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.Diabetes Care. 1999 Mar;22 Suppl 2:B65-71. Diabetes Care. 1999. PMID: 10097902 Review.
-
AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view.Nutr Metab Cardiovasc Dis. 2013 Oct;23(10):913-9. doi: 10.1016/j.numecd.2013.04.004. Epub 2013 Jun 17. Nutr Metab Cardiovasc Dis. 2013. PMID: 23786818 Review.
-
Carbonyl stress and diabetic complications.Clin Chem Lab Med. 2003 Sep;41(9):1150-8. doi: 10.1515/CCLM.2003.178. Clin Chem Lab Med. 2003. PMID: 14598864 Review.
-
[Advanced glycation end products and hyperglycaemia].Tidsskr Nor Laegeforen. 2006 Jan 12;126(2):155-8. Tidsskr Nor Laegeforen. 2006. PMID: 16415936 Review. Norwegian.
Cited by
-
Examining the role of lipid mediators in diabetic retinopathy.Clin Lipidol. 2012 Dec 1;7(6):661-675. doi: 10.2217/clp.12.68. Clin Lipidol. 2012. PMID: 23646066 Free PMC article.
-
Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives.Biomolecules. 2022 Apr 4;12(4):542. doi: 10.3390/biom12040542. Biomolecules. 2022. PMID: 35454131 Free PMC article. Review.
-
B procyanidins of Annona crassiflora fruit peel inhibited glycation, lipid peroxidation and protein-bound carbonyls, with protective effects on glycated catalase.Sci Rep. 2019 Dec 16;9(1):19183. doi: 10.1038/s41598-019-55779-3. Sci Rep. 2019. PMID: 31844118 Free PMC article.
-
Renal-protective effect of nicousamide on hypertensive nephropathy in spontaneously hypertensive rats.Biomed Rep. 2013 Jan;1(1):34-40. doi: 10.3892/br.2012.11. Epub 2012 Sep 25. Biomed Rep. 2013. PMID: 24648890 Free PMC article.
-
Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment.Open Cardiovasc Med J. 2010 Nov 26;4:240-56. doi: 10.2174/1874192401004010240. Open Cardiovasc Med J. 2010. PMID: 21270942 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical